Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharmaceuticals.
Animals
Drug Development
/ methods
Drug Discovery
/ methods
Fluorine Radioisotopes
Fluorodeoxyglucose F18
/ adverse effects
Humans
Neoplasms
/ radiotherapy
Positron-Emission Tomography
/ methods
Radiation Oncology
/ methods
Radiochemistry
/ methods
Radiopharmaceuticals
/ adverse effects
Treatment Outcome
clinical translation
metabolism
positron emission tomography
radiochemistry
radiopharmaceuticals
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
06 07 2020
06 07 2020
Historique:
pubmed:
21
5
2020
medline:
8
6
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
Positron emission tomography (PET) has proven to be an invaluable tool in the staging and management of disease in oncology; however, [
Identifiants
pubmed: 32433888
doi: 10.1021/acs.molpharmaceut.0c00328
doi:
Substances chimiques
Fluorine Radioisotopes
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Fluorine-18
GZ5I74KB8G
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2245-2259Subventions
Organisme : Medical Research Council
ID : MR/J007986/1
Pays : United Kingdom